Intelligent Bio Solutions Inc. provided unaudited preliminary earnings guidance for the second quarter and six months ended December 31, 2023. The Company expects approximate unaudited revenue of $1.56 million for the six months ended December 31, 2023, representing a significant increase of 337% compared to the same period the prior year, and approximate unaudited revenue of $0.76 million for the second fiscal quarter ended December 31, 2023, representing an increase of 114% compared to the same period the prior year.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.36 USD | +0.85% | 0.00% | -42.29% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.29% | 6.4M | |
-30.47% | 9.3B | |
-8.02% | 3.1B | |
+26.88% | 2.87B | |
-14.31% | 2.17B | |
-18.21% | 1.75B | |
+65.95% | 1.5B | |
+30.33% | 807M | |
-1.97% | 759M | |
-27.55% | 532M |
- Stock Market
- Equities
- INBS Stock
- News Intelligent Bio Solutions Inc.
- Intelligent Bio Solutions Inc. Provides Unaudited Preliminary Earnings Guidance for the Second Quarter and Six Months Ended December 31, 2023